ArticleSubstance use : research and treatment
A Descriptive Study of Hallucinogen and Inhalant Detoxification Admissions From 2006 to 2022.
Article in Substance use : research and treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Detoxification is often identified as treating drug withdrawal. All drug classes except hallucinogens and inhalants include withdrawal as diagnostic criteria for a substance use disorder diagnosis. This descriptive study provides an analysis of detoxification admissions for individuals with hallucinogens or inhalants as their primary substance. Objectives: This research aimed to explore the characteristics of these detoxification admissions, focusing on demographics, substance use patterns, and treatment characteristics. Design: This retrospective study used annual cross-sectional data. Methods: Using the Treatment Episode Dataset Admissions 2006 to 2022 file, data from 8919 detoxification admissions over a 17-year period from publicly funded treatment facilities in the United States were examined. Results: During the 17-year period, n = 6761 and n = 2158 detoxification treatment episode admissions had the primary substance hallucinogens and inhalants, respectively. Polysubstance use was prevalent among both samples, with 66% among the hallucinogen sample and 48% among the inhalant sample, with alcohol, cannabis, and cocaine/crack being the most commonly co-used substances. A total of 2872 cases were identified as only having hallucinogens and/or inhalants without other drug classes as reported substances during admission. Conclusion: These preliminary findings highlight detoxification admissions among individuals with primary substances that do not meet diagnostic criteria for withdrawal. More research is needed to better understand the context of detoxification among individuals with hallucinogens or inhalants as their primary substance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.